Application of Baricitinib in Dermatology

References

• Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697–704. doi:10.1007/s40265-017-0723-3
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi:10.1146/annurev-med-051113-024537
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24. doi:10.1016/s0378-1119(02)00398-0
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatol. 2019;58(6):1122. doi:10.1093/rheumatology/kez002
   PubMed Web of Science ®Google Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. doi:10.1016/j.intimp.2020.106210
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves Eli Lilly’s baricitinib. Nat Rev Drug Discov. 2018;17(7):460. doi:10.1038/nrd.2018.112
   Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–3052. doi:10.1172/JCI98814
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 2018;33(11):1950–1959. doi:10.1093/ndt/gfx377
   PubMed Web of Science ®Google Scholar
• Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2020. doi:10.1136/annrheumdis-2020-218690
   Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi:10.1016/j.jaad.2016.12.005
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9. doi:10.1016/j.jaad.2018.01.018
   PubMed Web of Science ®Google Scholar
• Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020;31(1):33–40. doi:10.1080/09546634.2019.1577549
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343. doi:10.1001/jamadermatol.2020.3260
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6
   Google Scholar
• Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. DermatolTher. 2020;10(21):29–42. doi:10.1007/s13555-019-00347-w
   Web of Science ®Google Scholar
• Hiraganahalli Bhaskarmurthy D, Evan Prince S. Effect of Baricitinib on TPA-induced psoriasis like skin inflammation. Life Sci. 2021;279:119655. doi:10.1016/j.lfs.2021.119655
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276. doi:10.1111/bjd.14403
   PubMed Web of Science ®Google Scholar
• Di Domizio J, Castagna J, Algros MP, et al. Baricitinib-induced paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):e391–e393. doi:10.1111/jdv.16293
   PubMed Web of Science ®Google Scholar
• Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib. Australas J Dermatol. 2020;61(4):374–376. doi:10.1111/ajd.13348
   PubMed Web of Science ®Google Scholar
• Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125. doi:10.3389/fimmu.2021.790125
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. doi:10.1016/j.jaad.2017.04.1141
   PubMed Web of Science ®Google Scholar
• Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British association of dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–926. doi:10.1111/j.1365-2133.2012.10955.x
   PubMed Web of Science ®Google Scholar
• Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033–1048. doi:10.1111/bjd.16808
   PubMed Web of Science ®Google Scholar
• Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. doi:10.1038/nrdp.2017.11
   PubMed Web of Science ®Google Scholar
• Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–1525. doi:10.1056/NEJMra1103442
   PubMed Web of Science ®Google Scholar
• Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. doi:10.1016/j.jaci.2019.08.035
   PubMed Web of Science ®Google Scholar
• Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117. doi:10.1038/nature09114
   PubMed Web of Science ®Google Scholar
• King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847–853. doi:10.1016/j.jaad.2021.05.050
   PubMed Web of Science ®Google Scholar
• Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Rep. 2019;5(10):892–894. doi:10.1016/j.jdcr.2019.07.005
   PubMedGoogle Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor Baricitinib. EBiomedicine. 2015;2(4):351–355. doi:10.1016/j.ebiom.2015.02.015
   PubMed Web of Science ®Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
   PubMed Web of Science ®Google Scholar
• Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2021;81(3):335–343. doi:10.1136/annrheumdis-2021-221276
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018;14(11):945–956. doi:10.1080/1744666X.2018.1504678
   PubMed Web of Science ®Google Scholar
• Dai Z, Chen J, Chang Y, Christiano AM. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight. 2021;6:7. doi:10.1172/jci.insight.142205
   Web of Science ®Google Scholar
• Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235–1242. doi:10.1021/acschembio.9b00188
   PubMed Web of Science ®Google Scholar
• Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62–70.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar